The Medical Letter on Drugs and Therapeutics
Aclidinium Bromide (Tudorza Pressair) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved aclidinium bromide (Tudorza Pressair – Forest), an orally-inhaled long-acting anticholinergic, for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD).

MAINTENANCE TREATMENT OF COPD — In patients with moderate to severe disease, regular treatment with a long-acting bronchodilator can improve lung function, relieve symptoms, decrease the frequency of exacerbations, and improve quality of life. The addition of an inhaled corticosteroid is recommended for patients with severe disease who experience frequent exacerbations.1

CLINICAL STUDIES — Two randomized, double-blind trials in 375 and 542 patients, all with moderate to severe COPD (baseline mean forced expiratory volume in 1 second [FEV1] 1.33-1.51 L), found that aclidinium 400 mcg inhaled twice ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aclidinium Bromide (Tudorza Pressair) for COPD
Article code: 1405b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian